Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
about
Activation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatasesA small CDC25 dual-specificity tyrosine-phosphatase isoform in Arabidopsis thalianaModulating splicing with small molecular inhibitors of the spliceosomeSmall molecule tools for functional interrogation of protein tyrosine phosphatasesEngaged for survival: From cadherin ligation to STAT3 activationDiscovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic ShuttlingBioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis.A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.Image-based screening for the identification of novel proteasome inhibitors.Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments.Targeting PTPs with small molecule inhibitors in cancer treatmentA FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs.Cysteine 81 is critical for the interaction of S100A4 and myosin-IIADual-Specificity Phosphatase CDC25A/B Inhibitor Identified from a Focused Library with Nonelectrophilic Core StructureK vitamins, PTP antagonism, and cell growth arrest.Dual-specificity phosphatases as targets for antineoplastic agents.The R(h)oads to Stat3: Stat3 activation by the Rho GTPases.Small Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression.Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cellsA quantitative high-throughput in vitro splicing assay identifies inhibitors of spliceosome catalysis.Differential Roles for DUSP Family Members in Epithelial-to-Mesenchymal Transition and Cancer Stem Cell Regulation in Breast Cancer.Kizuna is a novel mitotic substrate for CDC25B phosphataseCDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.Targeting the PTPome in human disease.CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.Targeting cell division cycle 25 homolog B to regulate influenza virus replication.Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B.1,4-naphthoquinones: from oxidative damage to cellular and inter-cellular signaling.Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target.Insights into the interaction of high potency inhibitor IRC-083864 with phosphatase CDC25.G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).Activation of maxi-anion channel by protein tyrosine dephosphorylation.Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase.Combination of pantothenamides with vanin inhibitors as a novel antibiotic strategy against gram-positive bacteria.Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.Synthesis and biological evaluation of caulibugulones A-E.
P2860
Q24306579-24B7E8F5-B81E-45BA-8634-2B2866343FC9Q24561880-0B06BDB1-7377-4A30-ACED-35D4F00A5692Q26738664-EE0C073B-1781-47B5-BB0D-114B8AF6A988Q26852276-009922FC-9FBE-45A5-88D6-7BDB205087F7Q27006477-2351F278-DD03-4D87-86A4-8DEC3E413F01Q28554890-65E83946-FD13-4F4C-8CBB-39AFB03722F6Q30436347-E95D79AA-2E03-4331-BAB7-9A4D62E69C05Q30859046-B66A7D15-4BBA-43DB-B5C4-89D9CD381A1AQ33222512-84AE64CC-436A-49E3-A34D-001133EF6025Q33268487-BEB8BEDC-B234-4D87-AF40-83AA3DB5625AQ33376019-4E2B0266-0F48-4E60-933F-8ED83A5FF890Q33468576-4A4EA019-97B8-4500-9A68-0FEEDF3D515BQ33523595-D300812D-2D7E-4811-80F4-647E33422C4FQ33554884-EF8FCB45-5519-4505-B084-F7B7C3F3729FQ33939476-E1E5B72E-9FB2-4032-BBE7-578459CBE55DQ33958590-819D9BD3-B186-4490-BB1A-6EFFF39F0EE9Q34233935-D36097D5-C51A-4456-80ED-B2FC371F96E8Q34972770-63AEBD52-15A4-4912-83E9-7C04DE7F61D5Q35013977-1C12929A-7A71-4463-A3FF-A23BF9A3CC5FQ35086590-4A88070C-AEB3-428E-A490-885D4FF56341Q35493037-F66A0308-A5E9-493E-97F2-FFE72943296DQ35810554-E948D8D2-7546-49AB-9941-D12DFDEA17E4Q35826664-35BE2DFB-019E-41A0-B1A5-AB4464928CB1Q35918045-43BEA032-4A89-4477-B507-454B3E96A031Q36189477-804BF9CB-BDB7-40B8-B8BC-142491C83ECCQ36305952-E121FA3B-BA86-45C2-A42B-405A2FD37228Q36379394-D91E0007-292A-4EF5-AEE1-C26CEA672330Q36545966-57C21400-F2D2-403E-99CC-C51074093531Q37336657-7FC02E39-7ECE-4270-BD9A-A4946DFC64E3Q37364667-6D56F54D-12B7-43D4-922A-39ABF7E9A95DQ38251996-24BA92B3-1ECF-4C44-A23C-F6170EA4ED98Q38268221-FF921A0D-504C-4E15-B87B-AF0D8B33E2B1Q38675402-E2D00098-D837-4BA5-AA09-8CE8B28E753CQ39038050-32C7954B-A332-4412-8A9C-9C45ADAB1553Q39687262-B88C2122-FBBB-4A2B-BE3A-DA0996F3B139Q39816332-8BA59B9C-DFD7-4459-B1FB-18C1D0762411Q40405860-A3737A75-4232-4F4C-9FC4-C5C11855AB92Q41976407-B35FFC77-D512-48AD-93B6-00F461B7E355Q43461214-4B2F68A2-F39A-4621-AD95-C01A388E8C08Q44998108-C397DC27-D1E9-462C-8040-E3EAD17364A9
P2860
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Identification of a potent and ...... ficity phosphatase inhibitors.
@en
Identification of a potent and ...... ficity phosphatase inhibitors.
@nl
type
label
Identification of a potent and ...... ficity phosphatase inhibitors.
@en
Identification of a potent and ...... ficity phosphatase inhibitors.
@nl
prefLabel
Identification of a potent and ...... ficity phosphatase inhibitors.
@en
Identification of a potent and ...... ficity phosphatase inhibitors.
@nl
P2093
P356
P1476
Identification of a potent and ...... ficity phosphatase inhibitors.
@en
P2093
Beomjun Joo
Daniel W Zaharevitz
Douglas A Mitchell
Eileen C Southwick
Kaoru Nemoto
Katharine E Pestell
Kathleen Cooley
Rick Gussio
William Furey
P304
P356
10.1124/MOL.61.4.720
P577
2002-04-01T00:00:00Z